219 related articles for article (PubMed ID: 14718798)
1. Mechanism of taxane neurotoxicity.
Hagiwara H; Sunada Y
Breast Cancer; 2004; 11(1):82-5. PubMed ID: 14718798
[TBL] [Abstract][Full Text] [Related]
2. Neurotoxicity of taxanes: symptoms and quality of life assessment.
Kuroi K; Shimozuma K
Breast Cancer; 2004; 11(1):92-9. PubMed ID: 14718800
[TBL] [Abstract][Full Text] [Related]
3. Taxane induced neuropathy in patients affected by breast cancer: Literature review.
De Iuliis F; Taglieri L; Salerno G; Lanza R; Scarpa S
Crit Rev Oncol Hematol; 2015 Oct; 96(1):34-45. PubMed ID: 26004917
[TBL] [Abstract][Full Text] [Related]
4. Managing taxane toxicities.
Markman M
Support Care Cancer; 2003 Mar; 11(3):144-7. PubMed ID: 12618923
[TBL] [Abstract][Full Text] [Related]
5. Techniques for the neurological examination of taxane-induced neuropathy.
Ohsumi S; Sunada Y
Breast Cancer; 2004; 11(1):86-91. PubMed ID: 14718799
[TBL] [Abstract][Full Text] [Related]
6. [Expert consensus on standardized management of taxane-related peripheral neuropathy].
Taxane-related Peripheral Neuropathy Standardized Management Group
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):170-179. PubMed ID: 32252195
[TBL] [Abstract][Full Text] [Related]
7. Management of toxicities associated with the administration of taxanes.
Markman M
Expert Opin Drug Saf; 2003 Mar; 2(2):141-6. PubMed ID: 12904114
[TBL] [Abstract][Full Text] [Related]
8. Treatment and care of neurotoxicity from taxane anticancer agents.
Makino H
Breast Cancer; 2004; 11(1):100-4. PubMed ID: 14718801
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
Park SB; Krishnan AV; Lin CS; Goldstein D; Friedlander M; Kiernan MC
Curr Med Chem; 2008; 15(29):3081-94. PubMed ID: 19075655
[TBL] [Abstract][Full Text] [Related]
10. Taxane-induced neurotoxicity: Pathophysiology and therapeutic perspectives.
da Costa R; Passos GF; Quintão NLM; Fernandes ES; Maia JRLCB; Campos MM; Calixto JB
Br J Pharmacol; 2020 Jul; 177(14):3127-3146. PubMed ID: 32352155
[TBL] [Abstract][Full Text] [Related]
11. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
[TBL] [Abstract][Full Text] [Related]
12. Advances in taxane therapy for metastatic breast cancer.
ONS News; 2004; 19(9 Suppl):75-6. PubMed ID: 15478598
[TBL] [Abstract][Full Text] [Related]
13. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats.
Persohn E; Canta A; Schoepfer S; Traebert M; Mueller L; Gilardini A; Galbiati S; Nicolini G; Scuteri A; Lanzani F; Giussani G; Cavaletti G
Eur J Cancer; 2005 Jul; 41(10):1460-6. PubMed ID: 15913989
[TBL] [Abstract][Full Text] [Related]
14. Current methods for the assessment and management of taxane-related neuropathy.
Smith EM
Clin J Oncol Nurs; 2013 Feb; 17 Suppl():22-34. PubMed ID: 23360700
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of taxane neuropathy.
Kudlowitz D; Muggia F
Anticancer Drugs; 2014 May; 25(5):495-501. PubMed ID: 24300917
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiological and phenotypic profiles of taxane-induced neuropathy.
Timmins HC; Li T; Huynh W; Kiernan MC; Baron-Hay S; Boyle F; Goldstein D; Park SB
Clin Neurophysiol; 2020 Aug; 131(8):1979-1985. PubMed ID: 32291143
[TBL] [Abstract][Full Text] [Related]
17. Motor neuropathy due to docetaxel and paclitaxel.
Freilich RJ; Balmaceda C; Seidman AD; Rubin M; DeAngelis LM
Neurology; 1996 Jul; 47(1):115-8. PubMed ID: 8710063
[TBL] [Abstract][Full Text] [Related]
18. Taxane and epothilone-induced peripheral neurotoxicity: From pathogenesis to treatment.
Tamburin S; Park SB; Alberti P; Demichelis C; Schenone A; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S40-S51. PubMed ID: 31647157
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
20. A Difference in the Incidences of Hypersensitivity Reactions to Original and Generic Taxanes.
Ratanajarusiri T; Sriuranpong V; Sitthideatphaiboon P; Poovoravan N; Vinayanuwat C; Parinyanitikul N; Angspatt P; Thawinwisan W; Tanasanvimon S
Chemotherapy; 2017; 62(2):134-139. PubMed ID: 27997900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
